Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in not only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, May 13, 2025. I will now turn the call over to Lisa D. Francesco, SVP, Investor Relations and Corporate Communications for Lexicon. Please go ahead, Lisa. Thank you, Shannon. Good afternoon and welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call. Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director, and Scott Chianti, Senior Vice President and Chief Financial Officer. Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, will join us for Q&A. Earlier this afternoon, Lexicon issued a press release announcing our financial results for the first quarter of 2025. which is available on our website at www.lexpharma.com and through our SEC filing. A webcast of this call, along with a slide presentation, is also available on our website. During this call, we will review the information provided in the release, provide a corporate update, and then use the remainder of our time to answer your questions. Before we begin, let me remind you that we will be making forward-looking statements, including statements related to the safety, efficacy, clinical development, regulatory status, and therapeutic and commercial potential of pilivapidin LX9851 Cetagliflozin, and our other drug programs, as well as our business generally. These statements may include characterizations and projections related to the clinical development, regulatory status, and market opportunity for our drug programs, and the commercial performan...